Valuation Edwards Lifesciences Corporation
Stocks
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 89.66 USD | +3.12% |
|
+3.44% | +5.17% |
| 06-16 | Edwards Lifesciences Seen Benefiting From CMS Transcatheter Aortic Valve Replacement Rule, RBC Says | MT |
| 06-11 | Edwards Lifesciences Set to Benefit from TAVR Coverage Update, RBC Says | MT |
Company Valuation: Edwards Lifesciences Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,883 | 46,128 | 46,246 | 43,663 | 49,471 | 51,626 | - | - |
| Change | - | -42.97% | 0.25% | -5.58% | 13.3% | 4.36% | - | - |
| Enterprise Value (EV) 1 | 80,616 | 45,956 | 45,198 | 40,285 | 45,843 | 48,144 | 46,554 | 44,711 |
| Change | - | -42.99% | -1.65% | -10.87% | 13.8% | 5.02% | -3.3% | -3.96% |
| P/E | 54.4x | 30.6x | 33.2x | 10.6x | 46.6x | 32x | 27.4x | 24.4x |
| PBR | 13.9x | 7.82x | 6.99x | 4.36x | 4.79x | 4.72x | 4.28x | 4.09x |
| PEG | - | 12.14x | -5.79x | 0x | -0.6x | 0.6x | 1.6x | 2x |
| Capitalization / Revenue | 15.5x | 8.57x | 7.7x | 8.03x | 8.15x | 7.65x | 6.97x | 6.34x |
| EV / Revenue | 15.4x | 8.54x | 7.53x | 7.41x | 7.56x | 7.13x | 6.28x | 5.49x |
| EV / EBITDA | 46.6x | 23.7x | 24.1x | 24.1x | 25.5x | 22.7x | 19.6x | 16.7x |
| EV / EBIT | 50.6x | 25.6x | 26.1x | 26.6x | 27.9x | 24.6x | 21.2x | 18.1x |
| EV / FCF | 57.3x | 47.2x | 47.9x | 139x | 34.3x | 35.3x | 27.5x | 23.1x |
| FCF Yield | 1.74% | 2.12% | 2.09% | 0.72% | 2.91% | 2.83% | 3.64% | 4.33% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 2.38 | 2.44 | 2.3 | 6.97 | 1.83 | 2.804 | 3.273 | 3.671 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5,232 | 5,382 | 6,005 | 5,440 | 6,068 | 6,748 | 7,411 | 8,146 |
| EBITDA 1 | 1,729 | 1,936 | 1,879 | 1,670 | 1,800 | 2,122 | 2,372 | 2,682 |
| EBIT 1 | 1,594 | 1,796 | 1,734 | 1,514 | 1,644 | 1,959 | 2,195 | 2,466 |
| Net income 1 | 1,503 | 1,522 | 1,402 | 4,175 | 1,074 | 1,624 | 1,891 | 2,115 |
| Net Debt 1 | -267 | -172.7 | -1,048 | -3,378 | -3,628 | -3,482 | -5,073 | -6,915 |
| Reference price 2 | 129.55 | 74.61 | 76.25 | 74.03 | 85.25 | 89.66 | 89.66 | 89.66 |
| Nbr of stocks (in thousands) | 624,334 | 618,260 | 606,500 | 589,800 | 580,300 | 575,800 | - | - |
| Announcement Date | 1/26/22 | 1/31/23 | 2/6/24 | 2/11/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 31x | 6.9x | 21.95x | -.--% | 50.07B | |
| 23.5x | 4.3x | 16.57x | 0.4% | 174B | |
| 44.28x | 11.59x | 25.94x | -.--% | 143B | |
| 28.54x | - | - | 0.8% | 127B | |
| 16.74x | 3.47x | 11.19x | -.--% | 67.78B | |
| 18.19x | 2.1x | 10.77x | 2.9% | 43.84B | |
| 24.61x | 4.91x | 16.91x | 0.81% | 35.78B | |
| 43.29x | 6.1x | 18.76x | -.--% | 35.07B | |
| 14.21x | 1.6x | 8.95x | 0.24% | 28.99B | |
| 18.04x | 4.74x | 12.22x | 1.27% | 27.62B | |
| Average | 26.24x | 5.08x | 15.92x | 0.64% | 73.3B | |
| Weighted average by Cap. | 28.42x | 6.01x | 17.78x | 0.5% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EW Stock
- Valuation Edwards Lifesciences Corporation
Select your edition
All financial news and data tailored to specific country editions
